Editorial for “Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer”

2020 ◽  
Vol 52 (1) ◽  
pp. 246-247
Author(s):  
Sharon E. Clarke
Keyword(s):  
Pancreatic Cancer ◽  
Preoperative Evaluation ◽  
Early Recurrence ◽  
Multiparametric Mri ◽  
Resectable Pancreatic Cancer

scholarly journals Preoperative scoring system to predict early recurrence after surgery for resectable pancreatic cancer: a multi-center retrospective study

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S292-S293
Author(s):  
D. Nobuoka ◽  
R. Yoshida ◽  
M. Hioki ◽  
D. Sato ◽  
T. Kojima ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Retrospective Study ◽  
Scoring System ◽  
Early Recurrence ◽  
Resectable Pancreatic Cancer

scholarly journals Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature

2019 ◽  
Vol 8 (11) ◽  
pp. 1922 ◽  
Author(s):  
Oneda ◽  
Zaniboni
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Chemotherapy ◽  
Adjuvant Therapy ◽  
Performance Status ◽  
Neoadjuvant Treatment ◽  
Early Recurrence ◽  
Current Treatment ◽  
R0 Resection ◽  
Resectable Pancreatic Cancer ◽  
Advantages And Disadvantages

The outcome of pancreatic cancer is poor, with a 9% 5-year survival rate. Current treatment recommendations in the 10%–20% of patients who present with resectable disease support upfront resection followed by adjuvant therapy. Until now, only early complete surgical (R0) resection and adjuvant chemotherapy (AC) with either FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) or nab-paclitaxel plus gemcitabine have been shown to prolong the survival. However, up to 30% of patients do not receive adjuvant therapy because of the development of early recurrence, postoperative complications, comorbidities, and reduced performance status. The aims of neoadjuvant chemotherapy (NAC) are to identify rapidly progressing patients to avoid futile surgery, eliminate micrometastases, increase the feasibility of R0 resection, and ensure the completion of multimodal treatment. Neoadjuvant treatments are effective, but there is no consensus on their use in resectable pancreatic cancer (RPC) because of its lack of a survival benefit over adjuvant therapy. In this review, we analyze the advantages and disadvantages of the two therapeutic approaches in RPC. We need studies that compare the two approaches and can identify the appropriate sequence of adjuvant therapy after neoadjuvant treatment and surgery.

scholarly journals Preoperative predictors for early recurrence of resectable pancreatic cancer

2017 ◽  
Vol 15 (1) ◽  
Author(s):  
Kohei Nishio ◽  
Kenjiro Kimura ◽  
Ryosuke Amano ◽  
Sadaaki Yamazoe ◽  
Go Ohrira ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Recurrence ◽  
Resectable Pancreatic Cancer ◽  
Preoperative Predictors

A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence

Pancreas ◽  
2018 ◽  
pp. 1 ◽  
Author(s):  
Hiroshi Kurahara ◽  
Kosei Maemura ◽  
Yuko Mataki ◽  
Masahiko Sakoda ◽  
Satoshi Iino ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Therapeutic Strategy ◽  
Early Recurrence ◽  
Resectable Pancreatic Cancer
Sign in / Sign up

Export Citation Format

Share Document